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background:  Patients with moderate to severe chronic kidney disease (CKD) are poorly represented in clinical trials of cardiac 
resynchronization therapy (CRT).
Methods: We conducted an inverse probability weighted analysis of 15,623 CRT-eligible patients (EF<35%, QRS>120ms, NYHA III/IV) 
with Stage III-V CKD in the NCDR© Implantable Cardioverter Defibrillator (ICD) Registry™, comparing outcomes between patients who 
received CRT with ICD (CRT-D; n=13,687, 87%) vs. ICD (n=1,936, 13%). Rates of patients with CKD III, IV, and V were 84%, 13.5%, 
and 2.5%. Outcomes were obtained via Medicare claims. The primary endpoint of heart failure hospitalization (HFH) or death and the 
secondary endpoint of death were assessed with Cox proportional hazards models. Other endpoints were assessed using Fine-Gray 
models. Control events were used to assess adequacy of statistical adjustment.
results:  After adjustment, CRT-D use was associated with lower rates of HFH or death (HR 0.81, CI 0.75-0.88, p<0.0001)(Figure 1a), 
death (HR 0.83, CI 0.76-0.91, p<0.0001)(Figure 1b), and HFH (HR 0.83, CI 0.75-0.91, p<0.001). There was no association between CRT-D 
use and progression to end stage renal disease (p=0.78). (pinteration= NS across CKD classes for these outcomes). CRT-D was not 
associated with control events: gastrointestinal bleed (p=0.45) or bone disorder/fracture (p=0.37).
Conclusion:  In a representative cohort, CRT-D use was associated with lower rates of HFH and death among patients with moderate to 
severe CKD.
